Navigating the U.S. Food and Drug Administration (FDA) review process can be challenging for food and ingredient companies, especially when timelines do not move as expected and GRAS Notice delays begin to affect launch plans, commercial commitments, and regulatory certainty. Even when a submission appears complete, extended review periods can disrupt internal planning and create pressure across business teams.